ନିଲୁଟାମାଇଡ

ନିଲୁଟାମାଇଡ
Clinical data
Pronunciation	nye-LOO-tah-mide
Trade names	Nilandron, Anandron
Synonyms	RU-23908
AHFS/Drugs.com	monograph
MedlinePlus	a697044
Pregnancy; category	US: C (Risk not ruled out) ; ;
Routes of; administration	By mouth
Legal status
Legal status	℞ (Prescription only);
Pharmacokinetic data
Bioavailability	Good
Protein binding	80–84%
Metabolism	Liver (CYP2C19, FMO)
Metabolites	At least 5, some active
Elimination half-life	Mean: 56 hours (~2 days); Range: 23–87 hours
Excretion	Urine: 62%; Feces: <10%
Identifiers
	IUPAC name 5,5-Dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione;
ECHA InfoCard	100.153.268
Chemical and physical data
Formula	C12H10F3N3O4
Molar mass	୩୧୭.୨୨ g·mol−1
3D model (JSmol)	Interactive image;
Melting point	149 °C (300 °F)
	SMILES CC1(C(=O)N(C(=O)N1)C2=CC(=C(C=C2)[N+](=O)[O-])C(F)(F)F)C;
	InChI InChI=1S/C12H10F3N3O4/c1-11(2)9(19)17(10(20)16-11)6-3-4-8(18(21)22)7(5-6)12(13,14)15/h3-5H,1-2H3,(H,16,20) ; Key:XWXYUMMDTVBTOU-UHFFFAOYSA-N ;
(verify)

ଇଂରାଜୀ ଲିଙ୍କ

https://or.wikipedia.org/wiki/Nilutamide

ନିଲୁଟାମାଇଡ (ଇଂରାଜୀ ଭାଷାରେ Nilutamide), ନିଲାଣ୍ଡ୍ରନ୍ ଏବଂ ଆନନ୍ଦ୍ରନ୍ ଦୁଇଟି ବିକ୍ରୟ ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ପ୍ରୋଷ୍ଟେଟ କର୍କଟ ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୭] କିନ୍ନର ବା ଟ୍ରାନ୍ସଜେଣ୍ଡର ମହିଳାଙ୍କ ପାଇଁ ଏହା ନାରୀକରଣ ହରମୋନ୍ ଥେରାପିର ଏକ ଉପାଦାନ ଭାବରେ ମଧ୍ୟ ବ୍ୟବହୃତ ହୋଇଛି ।^[୮] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୭]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଉଷୁମ ଲାଲ ମୁହଁ, ଅନ୍ଧକାରରେ ଦେଖିବାର ଅକ୍ଷମତା, ଅଇ, କୋଷ୍ଠକାଠିନ୍ୟ, ଶୋଇବାରେ ଅସୁବିଧା ଏବଂ ଗାଇନେକୋମାଷ୍ଟିଆ ବା ସ୍ତନ ବୃଦ୍ଧି ହୋଇପାରେ ।^[୯] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଯୌନ ଅସୁବିଧା, ଓଷ୍ଟିଓପୋରୋସିସ୍, ମଦ୍ୟପାନ ଅସହିଷ୍ଣୁତା ହୋଇପାରେ ।^[୯] ^[୭] କ୍ୱଚିତ ଏହା ନିମୋନାଇଟିସ୍ ଏବଂ ଯକୃତର କ୍ଷତି ଘଟାଇପାରେ ।^[୭] ଏହି ପ୍ରତିକୂଳ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟା ଏହାର ବ୍ୟବହାରକୁ ସୀମିତ କରିଦେଇଛି ।^[୧୦]

ନିଲୁଟାମାଇଡ୍ ହେଉଛି ଏକ ନନ-ଷ୍ଟେରଏଡାଲ୍ ଆଣ୍ଟିଆଣ୍ଡ୍ରୋଜେନ୍ (NSAA) ଯାହା ଆଣ୍ଡ୍ରୋଜେନ୍ ରିସେପ୍ଟରର (ଆର୍) ଏକ ମନୋନୀତ ବିରୋଧୀ ଭାବରେ କାର୍ଯ୍ୟ କରିଥାଏ, ଯାହା ଆଣ୍ଡ୍ରୋଜେନର ପ୍ରଭାବକୁ ରୋକିଥାଏ ।^[୧୧] ପ୍ରୋଷ୍ଟେଟ କର୍କଟ ବୃଦ୍ଧି ଏବଂ ବଞ୍ଚିବା ପାଇଁ ଏହି ହରମୋନ୍ ଉପରେ ନିର୍ଭର କରୁଥିବାରୁ ଏହା ରୋଗର ପ୍ରଗତିକୁ ମନ୍ଥର କରିପାରେ | ^[୭]

୧୯୭୭ ମସିହାରେ ନିଲୁଟାମାଇଡ ଆବିଷ୍କୃତ ହୋଇଥିଲା ଏବଂ ୧୯୮୭ରେ ଚିକିତ୍ସା ପାଇଁ ଅନୁମୋଦନ କରାଯାଇଥିଲା ।^[୧୨] ^[୧୩] ଏହାକୁ ୧୯୯୬ରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଅନୁମୋଦନ କରାଯାଇଥିଲା ।^[୭] ବାଇକାଲୁଟାମାଇଡର ବିକଳ୍ପ ଭାବରେ ଏହା ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନର ଜରୁରୀ ଔଷଧର ତାଲିକାରେ ଲିପିବଦ୍ଧ ଅଛି ।^[୧୪] ଏହା ଏକ ସାଧାରଣ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ ।^[୧୫] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୧୫୦ ମିଗ୍ରା ବିଶିଷ୍ଟ ୩୦ଟି ବଟିକାର ମୂଲ୍ୟ ୨୦୨୧ ସୁଦ୍ଧା ପ୍ରାୟ ୧୬୦୦ ଡଲାର ଥିଲା ।^[୧୫]

ଆଧାର

↑ "Nilutamide (Nilandron) Use During Pregnancy". Archived from the original on 28 October 2020. Retrieved 4 October 2021.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ Michael C. Perry; Donald C. Doll; Carl E. Freter (30 July 2012). Perry's The Chemotherapy Source Book. Lippincott Williams & Wilkins. pp. 711–. ISBN 978-1-4698-0343-2.
↑ "Nilutamide - LiverTox". National Institutes of Health. Archived from the original on 24 September 2018. Retrieved 24 September 2018. In large registration clinical trials, ALT elevations occurred in 2% to 33% of patients during nilutamide therapy. The elevations were usually mild, asymptomatic and transient, rarely requiring drug discontinuation. In rare instances, clinically apparent acute liver injury has occurred during nilutamide therapy, but the number of published cases are few, and the agent appears to be far less hepatotoxic than flutamide.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ Thomas L. Lemke; David A. Williams (24 January 2012). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 1373–. ISBN 978-1-60913-345-0. Archived from the original on 14 September 2021. Retrieved 4 October 2021.
↑ Bruce A. Chabner; Dan L. Longo (8 November 2010). Cancer Chemotherapy and Biotherapy: Principles and Practice. Lippincott Williams & Wilkins. pp. 680–. ISBN 978-1-60547-431-1. Archived from the original on 27 July 2020. Retrieved 4 October 2021.
↑ ^୬.୦ ^୬.୧ Kolvenbag, Geert J. C. M.; Furr, Barrington J. A. (2009). "Nonsteroidal Antiandrogens". In V. Craig Jordan; Barrington J. A. Furr (eds.). Hormone Therapy in Breast and Prostate Cancer. Humana Press. pp. 347–368. doi:10.1007/978-1-59259-152-7_16. ISBN 978-1-60761-471-5. Although the t1/2 of nilutamide is h (mean 56 h) (39), suggesting that once-daily dosing would be appropriate, a three times per day regimen has been employed in most clinical trials.
↑ ^୭.୦ ^୭.୧ ^୭.୨ ^୭.୩ ^୭.୪ ^୭.୫ "Nilutamide Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 4 March 2016. Retrieved 13 November 2021.
↑ <Baudewijntje P.C. Kreukels; Thomas D. Steensma; Annelou L.C. de Vries (1 July 2013). Gender Dysphoria and Disorders of Sex Development: Progress in Care and Knowledge. Springer Science & Business Media. pp. 280–. ISBN 978-1-4614-7441-8. Archived from the original on 14 September 2021. Retrieved 4 October 2021.
↑ ^୯.୦ ^୯.୧ Richard A. Lehne (2013). Pharmacology for Nursing Care. Elsevier Health Sciences. pp. 1297–. ISBN 978-1-4377-3582-6. Archived from the original on 27 July 2020. Retrieved 4 October 2021.
↑ Vincent T. DeVita; Theodore S. Lawrence; Steven A. Rosenberg (18 March 2016). Prostate and Other Genitourinary Cancers: Cancer: Principles & Practice of Oncology. Wolters Kluwer Health. pp. 1006–. ISBN 978-1-4963-5421-1.
↑ "DailyMed - NILUTAMIDE tablet". dailymed.nlm.nih.gov. Archived from the original on 24 March 2021. Retrieved 13 November 2021.
↑ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 873–. ISBN 978-1-4757-2085-3.
↑ János Fischer; Christian Klein; Wayne E. Childers (16 April 2018). Successful Drug Discovery. Wiley. pp. 98–. ISBN 978-3-527-80868-7. Archived from the original on 28 October 2021. Retrieved 4 October 2021.
↑ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
↑ ^୧୫.୦ ^୧୫.୧ "Nilutamide Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 8 November 2016. Retrieved 13 November 2021.

[1] "Nilutamide (Nilandron) Use During Pregnancy". Archived from the original on 28 October 2020. Retrieved 4 October 2021.

[PerryDoll2012-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ Michael C. Perry; Donald C. Doll; Carl E. Freter (30 July 2012). Perry's The Chemotherapy Source Book. Lippincott Williams & Wilkins. pp. 711–. ISBN 978-1-4698-0343-2.

[LiverTox-3] "Nilutamide - LiverTox". National Institutes of Health. Archived from the original on 24 September 2018. Retrieved 24 September 2018. In large registration clinical trials, ALT elevations occurred in 2% to 33% of patients during nilutamide therapy. The elevations were usually mild, asymptomatic and transient, rarely requiring drug discontinuation. In rare instances, clinically apparent acute liver injury has occurred during nilutamide therapy, but the number of published cases are few, and the agent appears to be far less hepatotoxic than flutamide.

[LemkeWilliams2012-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ Thomas L. Lemke; David A. Williams (24 January 2012). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 1373–. ISBN 978-1-60913-345-0. Archived from the original on 14 September 2021. Retrieved 4 October 2021.

[ChabnerLongo2010-5] Bruce A. Chabner; Dan L. Longo (8 November 2010). Cancer Chemotherapy and Biotherapy: Principles and Practice. Lippincott Williams & Wilkins. pp. 680–. ISBN 978-1-60547-431-1. Archived from the original on 27 July 2020. Retrieved 4 October 2021.

[KolvenbagFurr2009-6] ୬.୦ ^୬.୧ Kolvenbag, Geert J. C. M.; Furr, Barrington J. A. (2009). "Nonsteroidal Antiandrogens". In V. Craig Jordan; Barrington J. A. Furr (eds.). Hormone Therapy in Breast and Prostate Cancer. Humana Press. pp. 347–368. doi:10.1007/978-1-59259-152-7_16. ISBN 978-1-60761-471-5. Although the t1/2 of nilutamide is h (mean 56 h) (39), suggesting that once-daily dosing would be appropriate, a three times per day regimen has been employed in most clinical trials.

[AHFS2021-7] ୭.୦ ^୭.୧ ^୭.୨ ^୭.୩ ^୭.୪ ^୭.୫ "Nilutamide Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 4 March 2016. Retrieved 13 November 2021.

[Kre2013-8] <Baudewijntje P.C. Kreukels; Thomas D. Steensma; Annelou L.C. de Vries (1 July 2013). Gender Dysphoria and Disorders of Sex Development: Progress in Care and Knowledge. Springer Science & Business Media. pp. 280–. ISBN 978-1-4614-7441-8. Archived from the original on 14 September 2021. Retrieved 4 October 2021.

[Leh2013-9] ୯.୦ ^୯.୧ Richard A. Lehne (2013). Pharmacology for Nursing Care. Elsevier Health Sciences. pp. 1297–. ISBN 978-1-4377-3582-6. Archived from the original on 27 July 2020. Retrieved 4 October 2021.

[De2016-10] Vincent T. DeVita; Theodore S. Lawrence; Steven A. Rosenberg (18 March 2016). Prostate and Other Genitourinary Cancers: Cancer: Principles & Practice of Oncology. Wolters Kluwer Health. pp. 1006–. ISBN 978-1-4963-5421-1.

[PI2021-11] "DailyMed - NILUTAMIDE tablet". dailymed.nlm.nih.gov. Archived from the original on 24 March 2021. Retrieved 13 November 2021.

[Elks2014-12] J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 873–. ISBN 978-1-4757-2085-3.

[Fisc2018-13] János Fischer; Christian Klein; Wayne E. Childers (16 April 2018). Successful Drug Discovery. Wiley. pp. 98–. ISBN 978-3-527-80868-7. Archived from the original on 28 October 2021. Retrieved 4 October 2021.

[WHO22nd-14] World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

[GX2021-15] ୧୫.୦ ^୧୫.୧ "Nilutamide Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 8 November 2016. Retrieved 13 November 2021.

[୩]

[୧]

[୨]

[୪]

[୫]

[୬]

[୭]

[୮]

[୯]

[୧୦]

[୧୧]

[୧୨]

[୧୩]

[୧୪]

[୧୫]